Novel caveolin modulators as therapeutics for uveitis

新型小窝蛋白调节剂治疗葡萄膜炎

基本信息

批准号：
8779645
负责人：
David D Eveleth
金额：
$ 20.89万
依托单位：
E AND B TECHNOLOGIES, LLC
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-01 至 2017-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8779645
关键词：
Acute Adverse event Affect Age Animal Model Antigens Autoimmune encephalitis Blindness Blood Vessels Caveolae Caveolins Cells Chronic Chronic Disease Clinical Clinical Trials Collaborations Development Disease Dose Drug Kinetics Edema Elements Experimental Models Extravasation Generations Genus Mycobacterium Goals Gold Health Sciences Human Hybrid Cells Immunomodulators Immunosuppressive Agents Inflammation Inflammatory Laboratories Lead Leukocytes Modeling Mus Oregon Oryctolagus cuniculus Outcome Measure Patients Peptides Pharmaceutical Preparations Phase Process RIII Mouse Research Research Proposals Retinal Route Saturn&apos s Moon Phoebe Signal Transduction Technology Therapeutic Toxic effect Toxicology Universities Uveitis Vascular Permeabilities Vision Visual impairment Work analog autoimmune uveitis base disability improved inflammatory modulation intravitreal injection killings migration mouse model novel novel therapeutics prevent primary outcome public health relevance research clinical testing research study response retinal damage scaffold

项目摘要

DESCRIPTION (provided by applicant): Novel caveolin modulators as therapeutics for uveitis Project Summary This research proposal seeks to develop a novel therapy for uveitis based upon modulation of inflammatory signaling via caveolae. Uveitis drives 5-20% of blindness, affecting people of working age and producing significant disability in patients with chronic disease. Caveolin modulators such as cavtratin are known to be able to modulate inflammatory signaling including edema and leukocyte migration, key elements of the pathogenic cascade in uveitis. E&B Technologies is developing an improved, second generation cavtratin, CVX-001, for the treatment of uveitis. The project goal is to demonstrate that CVX-001 can prevent retinal inflammation in mouse and rabbit models of uveitis and, in phase II, IND enabling work completed. Longer term, proof of concept in human clinical testing will be pursued and the clinical trials needed for regulatory approval will be conducted. Successful completion of this project will establish a new therapeutic option for uveitis sufferers with a reduction in blindness and visual impairment. 1

描述（申请人提供）：新型的小窝蛋白调节剂作为葡萄膜炎项目的治疗剂总结本研究提案旨在基于通过小窝对炎症信号传导的调节来开发一种新型葡萄膜炎疗法。葡萄膜炎驱动着5-20％的失明，影响有效年龄的人并在患有慢性疾病的患者中产生严重的残疾。众所周知，卡韦洛尔蛋白调节剂（如孢子蛋白酶）能够调节炎症信号传导，包括水肿和白细胞迁移，葡萄膜炎病原级联的关键元素。 E＆B Technologies正在开发改进的第二代Cavtratin，CVX-001，用于治疗葡萄膜炎。项目目标是证明CVX-001可以防止小鼠和葡萄膜炎的兔模型的视网膜炎症，以及在II期中，可以完成工作。从长远来看，将进行人类临床测试中的概念证明，并将进行监管批准所需的临床试验。该项目的成功完成将为葡萄炎患者建立新的治疗选择，而失明减少了和视觉障碍。 1